A better diagnosis for a better Medical Management.

The first blood test for patients suffering from mild cognitive impairments - A novel test to diagnose Alzheimer and other neurodegenerative diseases - A test soon available on medical prescription or for clinical research.

  • The first reliable and non-invasive test of Alzheimer's disease.

  • A test to assist patient cohort selection  and monitoring of  clinical trials to test new drug candidates.


Some words about us

Alzohis is a young innovative biotechnology company created in 2014.


2016 - Hadrien Peltier

Alzohis provides a new molecular diagnostic test for Alzheimer’s disease. A novel combination of biomarkers leading to a typical “signature” detectable in the blood. This signature is able to discriminate patients suffering from Alzheimer’s disease (AD) from healthy ones and from other neurodegenerative diseases. Alzohis, a new tool for physicians. This diagnosis is based among others on the measure of specific blood biomarkers. Today this type of score, based on a computational model, is relatively well accepted by the medical community (business model identical to diagnosis of trisomy 21, hepatitis C ...).

Alzheimer's disease is so common that it is currently an issue of global general interest. It also affects the family of sufferers, putting them under intense psychological, social and financial pressure. We need an earlier diagnosis, in order to provide better care!

Alzohis has expertises in : (i)Biomolecular analysis, (ii) Development of algorithms, (iii) Management of big data in a secure environment.

Alzohis has the ambition to provide a  revolutionary diagnostic tools to help neurologists and specialists to secure their diagnosis.

This disease is detected very late, on average 3-4 years after the first symptoms. Alzohis develops the first reliable non-invasive molecular diagnostic method. It's clear now that Alzheimer's begins decades before symptoms start and that the best treatments will likely begin early, before there is too much damage to reverse.

The development of new curative treatments of AD is strongly correlated  to the conception of earlier and more specific diagnoses.  Biomolecular-based diagnostic methods currently available for Alzheimer’s disease are still insufficient in terms of precocity and performances. This slows the development of new pharmaceutical molecules with curative intent.

How does it work?



    The physician prescribes the Alzohis Test when his patient presents cognitive impairments or clinical symptoms.


    As soon as possible, the patient goes to a medical  laboratory close to his home for a standard blood test

  • 3 - A simple blood test

    The analysis is performed  by the laboratory. Less than one hour is required.

  • 4 - Results are sent

    The laboratory or the physician connects through a secured connection with the Alzohis platform and sends the blood test results.

  • 5 - Get Alzohis's score

    The Alzohis tests are calculated in our secured environment, using our powerful algorithms.

  • 6 - Diagnosis proposed

    The result sheet listing all the relevant information is immediately available for the doctor.


You are a patient

Discovered in 1906 by Aloïs Alzheimer, Alzheimer's disease is a brain disorder. It leads to a progressive loss of neurons.

The moment when the diagnosis is made during the patient’s life. Three different diagnoses were considered, represented by a patient P, “early patient” diagnosed at mild stage, a patient M, “average patient” diagnosed at the start of the moderate stage and a patient T, “late patient” diagnosed at the end of the moderate stage.

You are a physician

We provide revolutionary diagnostic tools to help neurologists and specialists to better secure your diagnosis.

Alzheimer's disease is a major medical problem, with a prevalence in the developed countries of more than 1%, which greatly increases with age. It is clear now that alzheimer's disease begins decades before symptoms start and that the best treatments will likely begin early before there is too much damage to reverse. The current diagnostic strategies for Alzheimer's disease are still inadequate in terms of precocity and performances, slowing considerably the development of new pharmaceutical molecules with a curative intent.


2016 - Alain Verpillot

You are a biologist

The determination of plasma mono-amine levels is of clinical importance in the diagnosis of some tumors of the nervous system. The plasma concentrations of metabolites may then be several times above the upper reference limits. Also for scientific questions in the area of stress research and in sports, medicine mono-amines levels provide useful information. For  pharmacological functional tests, it is necessary to measure plasma levels.

The quantitative determination of blood metabolites is not only useful in differential diagnoses of hypertension but also for the evaluation of a number of other clinical and pharmacological aspects. The concentrations of these are indicative for the activity of the sympathetic nervous system, and are important parameters in congestive cardiac insufficiency, coronary heart disease, diabetes mellitus, arteriosclerosis, acute asthma, and others. 

Clinical research for biotech

Strategies and analytical methods are available for medical laboratories.

Better diagnosis for better treatment : The development of new curative treatments of AD is strongly linked to the conception of earlier and more specific diagnoses. Diagnostic methods currently available for Alzheimer’s disease and based on biochemical analyzes are still insufficient. This slows the development of new pharmaceutical molecules with curative possibilities.


2016 - Alain Verpillot

patients have dementia in the world
New cases of dementia in 2015
Patients were never diagnosed
New cases of dementia each day in the world

Simple and effective ways to distinguish dementia

Disruptive innovation in the diagnosis for patient suffuring from neurodegenerative diseases

Neurodegenerative diseases and dementia

Neurodegeneration is the umbrella term for the progressive loss of structure or functions of neurons, including the death of neurons. Many neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson's or Alzheimer's disease, Progressive supranuclear palsy and  Frontotemporal lobar degeneration occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or the death of neuron cells.

The most common early symptom is the difficulty to remember recent events (short-term memory loss). As the disease progresses, symptoms can include problems with language, disorientation (including getting lost easily), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, this person often withdraws from family and society. Gradually, bodily functions are lost, ultimately leading to death. Approximately 1 people per 100 population have AD.
Is a specific disorder that involves the death of neurons. ALS is characterized bystiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. This results in difficulty speaking, swallowing, and eventually breathing. Approximately 2.5 people per 100,000 population have ALS.
Also known as idiopathic or primary parkinsonism, hypokinetic rigid syndrome, or paralysis agitans, is adegenerative disorder of the central nervous systemmainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in thesubstantianigra, a region of the midbrain. The causes of this cell death are poorly understood. Approximately 8-18 people per 100,000 population have PD.
Also known as disorders of multiple system degeneration, is a group of neurodegenerative diseases featuring the classical features of Parkinson's disease (tremor, rigidity, akinesia/bradykinesia, postural instability) with additional features that distinguish them from simple idiopathic Parkinson's disease. Some considerAlzheimer's disease to be in this group. Parkinson-plus syndromes are either inherited genetically or occur sporadically. The atypical parkinsonian or Parkinson Plus syndromes are often difficult to differentiate from Parkinson's disease and each other.
Is a pathological process that occurs in frontotemporal dementia. It is characterized by atrophy in the frontal lobe and temporal lobe of the brain, with sparing of the parietal and occipital lobes. Approximately 2-9 people per 100,000 population have FTD.
Is a degenerative disease involving the gradual deterioration and death of specific volumes of the brain. Approximately 6 people per 100,000 population have SNP.

Dementia distribution

We're proud of our performances

A Powerful diagnosis of Alzheimer's disease




Only of false positives

Alzohis Diagnostic Score and Management

Alzohis, simple and non-invasive test to discriminate Alzheimer and other neurodegenerative diseases

Orientation to time 

Orientation to space








Alzohis Diagnosis Score

Diagnosis available immediatly for the doctor. Online generation / online access.

Do you know some amazing new drugs undergoing clinical trials?

Stratification of patients for efficiency can substantially reduce the number required to treat for benefit.

Let's Get Started

latest news


2016May 03

Event : Réseau Entreprendre Paris - Laureat 2015

Founder of Alzohis has pitched at Hôtel de Ville - Paris with Réseau Entreprendre.

2016Apr 15

Meeting of the Alzohis Committee

At this occasion, the Alzohis team will share news with all committee members, both scientific and strategic in order to define and plan together a road map and share an accurate vision for the project.

2015Dec 15

World Alzheimer Report 2015

An analysis of prevalence, incidence, cost and trends updates ADI's global dementia data. By carrying out a full update of previous systematic reviews, the report makes key recommendations to provide a global framework for action on dementia.

World Alzheimer Report 2015
2015 Nov 5

[Réseau Entreprendre Paris] - Laureate - 2015 promotion

Alzohis team is laureate of the 2015 promotion of Réseau Entreprendre Paris.

World Alzheimer Report 2015
2015Sep 21

Treatment and care

The Alzheimer Disease

There is no treatment currently available to cure dementia or to alter its progressive course. Numerous new treatments are being investigated in various stages of clinical trials. Much can be, however, offered to support and improve the lives of people with dementia and their caregivers and families. The principal goals for dementia care are:  (i) early diagnosis (ii) optimizing physical health, cognition, activity and well-being (iii) identifying and treating the accompanying physical illnesses (iv) detecting and treating behavioral and psychological symptoms (v) providing information and long-term support to caregivers.OMS 2015

2014Mars 10

Creation of Alzohis

On March 10, 2014, Alzohis was created by three co-founders Romain Verpillot, Myriam Taverna and Rudy Beaujean

Alzohis Launch March 10 2014

Alzohis Team


Romain Verpillot

HEC challenge+ , EMLYON, Ph.D. in analytical chemistry, laureate of Réseau Entreprendre Paris in 2015.

Marine Gaillard
Project Manager

Graduate of Law and Sciences Po Grenoble in Health. Regulatory strategies and market access.

Rudy  Beaujean

Computer science engineer specialized in security/network and systems on several production environments.

Hervé Thiriez
Operations Management

Ph.D. in Operations Research at MIT. Emeritus Professor of Management Science at Groupe HEC. Excel MVP.

Sign up for our newsletter now

Be amongst the first people to know about news and upcoming features

Frequently asked questions


Q:How to perform the Alzohistest?

A:Talk to your doctor. This test is performed only on medical prescription.

Q:When should out the Alzohis test be taken?

A:The test is effective from the first specific symptoms of certain neurodegenerative diseases. To find out, ask your specialist to confirm your cognitive score before performing the Alzohis test.

Q:What is this test?

A:A revolutionary diagnostic tool from a simple blood test to help neurologists and specialists better secure their diagnosis.

Q:Why take a test when there is no known cure for Alzheimer's disease?

A:It is important for us to learn about his disease to slow the appearence of frailty by an appropriate clinical monitoring which is most effective when it begins early.

Q:How does it work?

A:This diagnosis is based on, amongst other factors, the level of neurotransmitters from a simple blood test, read using an algorithm currently under development.

Q:When will this test will be available on the market?

A:You can receive our newsletter automatically by entering your email address on our website. Currently Alzohis completes clinical trials, and this test will be on the market later this year.

What they say about Alzheimer's disease

  • « Dementia is caused by a variety of diseases and injuries that primarily or secondarily affect the brain, such as Alzheimer's disease or stroke »

    OMS - Fact sheet N°362

  • « The Alzheimer’s Association works on a global, national and local level to enhance care and support for all those affected by Alzheimer’s and other dementias. We are here to help »

    The Alzheimer's Association -

  • « Being able to diagnose Alzheimer's disease more easily, earlier, and more accurately could have a marked effect on the design of clinical studies »

    Pr. Bruno Dubois -

  • « Studies of solanezumab for Alzheimer's disease have shown that there is a 36% rate of false diagnosis of Alzheimer's disease in clinical trials that were made in expert centres but based only on clinical criteria »

    Pr. Bruno Dubois -

Start connecting with us

Postal Address

28 Rue du Faubourg Poissonnière

75010 Paris


28 Rue du Faubourg Poissonnière

75010 Paris


Phone Number: +33 1 84 25 06 28